Can Wegovy Cause Depression? What the Evidence Actually Shows

What do the clinical trials actually say about Wegovy and depression?

The STEP 1 trial (the pivotal 68-week study that led to Wegovy's UK licence) involved over 1,900 adults and tracked a broad range of safety outcomes, including mood and psychological wellbeing. Rates of depression-related events were not significantly different between the semaglutide and placebo groups. That is the headline finding, and it holds across the wider STEP programme. The STEP 1 paper, published in the New England Journal of Medicine, is publicly available if you want to read the safety data yourself.

Separately, in 2023 and into 2024, regulators including the European Medicines Agency and the MHRA looked specifically at reports of suicidal thoughts and self-harm in people taking GLP-1 medicines, including semaglutide. Their review concluded that the available evidence did not establish a causal relationship. The NHS medicines page for semaglutide reflects this position: low mood and suicidal thoughts are listed as possible side effects to report, but they are not described as common or likely. Vigilance is appropriate; alarm is not.

None of this means mood cannot be affected during treatment. It means the medicine itself is not the established culprit.

If it isn't the medicine, why do some people feel low on Wegovy?

Several other factors tend to be at play. Nausea, fatigue, and disrupted eating patterns are common in the first weeks of treatment, and feeling physically unwell affects mood reliably. Eating less can sometimes mean eating less of foods that felt comforting, which is a subtler psychological adjustment than people expect. Some individuals also come to treatment carrying years of frustration with their weight, and the emotional experience of that history does not disappear because a medicine has started working.

There is also a known phenomenon in some people who lose weight relatively quickly: a period of psychological recalibration as their body and self-image shift. This is not unique to Wegovy or to GLP-1 treatment, it has been observed after bariatric surgery and intensive dietary programmes too. Understanding what is driving low mood on Wegovy is important before assuming the medicine is the cause.

If your mood is noticeably lower than before you started, that is worth raising with your prescriber. It should not simply be waited out.

Is there any suggestion Wegovy could actually help with mood?

This is an active area of research, and it cuts in an interesting direction. GLP-1 receptors exist in the brain, not only in the gut and pancreas. Some researchers are exploring whether semaglutide might have effects on the reward and motivation pathways that also play a role in mood regulation, and if you are curious about how amble semaglutide fits into this landscape, there is more detail available. Early signals from observational studies are cautiously intriguing, but they are far from conclusive, and the question of whether semaglutide could help with depression is not settled science.

What is more established is that significant weight loss, sustained over time, tends to be associated with improvements in self-esteem, mobility, energy, and (for many people) mood. Whether that is a direct biological effect or a consequence of feeling better physically is hard to separate. Our clinical team keeps a close eye on emerging evidence in this area. If you are interested in the broader question of whether Wegovy might benefit mental health, there is a dedicated page exploring that evidence in more detail.

What should you do if depression or low mood develops during treatment?

First: tell someone. That means your prescriber, your GP, or both. A pre-existing history of depression does not automatically rule out treatment with Wegovy, but it does mean closer monitoring is sensible. If you develop persistent low mood, changes in sleep, loss of interest in things you normally value, or any thoughts of self-harm, seek help promptly, do not wait for your next scheduled review.

The MHRA's Yellow Card scheme exists so that patients can report suspected side effects, including mood changes, directly. These reports contribute to ongoing safety monitoring for all licensed medicines. If you are prescribed Wegovy through a regulated service and something changes, the right move is to make contact rather than stop the medicine without clinical guidance. At nume, aftercare is available seven days a week for exactly this kind of concern. If you want to understand whether mood changes on Wegovy tend to resolve, that question has a dedicated answer too.

For anyone weighing up treatment more broadly, understanding the full cost picture is a useful step before a consultation. And when you are ready to talk through suitability with a clinician, checking your eligibility is the place to start.